argenx Q3 product sales rise 54% to $1.7 billion
Compartilhar
argenx (NASDAQ:ARGX) reported third-quarter 2026 global product net sales of $1.7 billion, up 54%, supported by continued VYVGART sales growth.
argenx (NASDAQ:ARGX) reported third-quarter 2026 global product net sales of $1.7 billion, up 54%, supported by continued VYVGART sales growth.
argenx (NASDAQ:ARGX) will discontinue its Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren's disease after an interim analysis found the trial could not meet its primary endpoint.
argenx (NASDAQ:ARGX) said its Phase 2 study of FB102 in adults with celiac disease met its primary endpoint, showing a statistically significant improvement versus placebo at day 78 with a p-value of 0.0176.
Argenx SE (NASDAQ:ARGX) shares are in focus after the U.S. Food and Drug Administration accepted a supplemental Biologics License Application for Vyvgart with Priority Review, potentially expanding the drug's reach to a difficult-to-treat subset of patients with generalized myasthenia gravis (gMG).
Argenx (ARGX) announced the discontinuation of its Phase 3 UplighTED studies for efgartigimod SC in Thyroid Eye Disease (TED) after an interim analysis by an Independent Data Monitoring Committee (IDMC) indicated futility.
